Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Burkitt Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 4Leukemia, Prolymphocytic 4Tumor Lysis Syndrome 3Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hyperuricemia 3Hodgkin Disease 3Congenital Abnormalities 3Primary Myelofibrosis 2Neoplasms 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Biphenotypic, Acute 2HIV Infections 2

Interventions

rasburicase 10Urate Oxidase 5Allopurinol 3Omeprazole 1Naproxen 1Febuxostat 1Colchicine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hyperuricemia × Allopurinol × Clear all
NCT02500641 2019-06-21

FORWARD

Menarini International Operations Luxembourg SA

Phase 4 Completed
196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Sanofi

Phase 3 Terminated
10 enrolled

Hyperuricemia

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡